American Gene Technologies® Pioneering Disease Solutions - We Are the Future of MedicineAddimmune™ Advancing a Cure for HIV Through Gene and Cell Therapy - Imagine a World Without HIV℠ABOUT MEAs CEO and founder of American Gene Technologies® (AGT™) and Addimmune™, I’m passionate about curing humanity’s most deadly diseases with gene and cell therapy. AGT’s new spin-off company, Addimmune, is developing a potential cure for HIV. Building upon the success of AGT’s HIV clinical trial, Addimmune is singularly focused on developing and commercializing an effective and lasting cure for HIV using gene and cell therapy.The healing potential of biotechnology has always fascinated me. I see the human cell as a biological computer, with DNA as its software operating system.Just like in man-made computers, a cell’s OS sometimes contains glitches or errors that make the cell function differently than intended. Those malfunctions can result in life-threatening diseases.The best way to cure those diseases is by fixing the underlying DNA — tweaking the cell’s software code to eliminate the glitch.That vision, and the techniques for repairing a cell’s DNA, continually drive me, AGT and Addimmune toward more innovation.I earned my BA degree in Economics from Harvard in 1981. I have more than 30 years of business and entrepreneurial experience, including founder or executive positions at a variety of Silicon Valley startups. Several of my companies were taken public and/or sold to public companies.WHO ARE WEAGT is a private biotech company pursuing cures and treatments for infectious diseases, cancers and monogenic disorders. We are supported by accredited investors and develop genetic medicines to address unmet medical needs in inherited or acquired diseases through the application of viral vector technology.Addimmune was founded in 2023 to cure HIV with promising gene and cell therapy technologies. This life-changing approach to HIV has been made possible by 15 years of pioneering research and development by AGT. The Phase 1 clinical trial of AGT103-T was so successful that AGT decided the HIV cure program deserves to be the sole focus of one business.Gene and Cell Therapy is Poised for Enormous Growth:Current gene and cell therapies are just the tip of a $5T market. According to Goldman Sachs, the gene and cell therapy industry could become 4X the size of the current pharmaceutical market.INVESTORS:Learn more about Addimmune’s and AGT’s pipelines here:https://www.addimmune.com/investorshttps://www.americangene.com/investors